DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Xanomeline
Xanomeline
WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No
Wo 2007/128674 A2
Muscarinic Acetylcholine Receptor
Treatment of Schizophrenia Course Director: Philip Janicak, M.D
Alzheimer's Disease Clinical Trials
Tetrahydropyridine: a Promising Heterocycle for Pharmacologically Active Molecules
Clinical Study Protocol
Dementia Summary
The Profile of Sabcomeline (SB-202026), a Functionally Selective M1 Receptor Partial Agonist, in the Marmoset
The Action of Xanomeline on Human Muscarinic Receptors Expressed in Chinese Hamster Ovary Cells
Investigation Into the Bioisosteric Approach in the Design, Synthesis
Serotonergic–Muscarinic Interaction Within the Prefrontal Cortex As a Novel Target to Reverse Schizophrenia-Related Cognitive Symptoms
Stembook 2018.Pdf
Clinical Trials and Late-Stage Drug Development in Alzheimer's Disease: an Appraisal from 1984 to 2014
Characterization of a CNS Penetrant, Selective M1 Muscarinic Receptor Agonist, 77-LH-28-1
A Straightforward Route to Enantiopure Pyrrolizidines And
Characterization of a Novel M1 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator Radioligand, [3H]PT-1284
Customs Tariff - Schedule
Top View
Review 0103 - 5053 $6.00+0.00
PIG&I* the USA. ALZHEIMER's DISEASE: CURRENT AND
Allosteric Modulation of the Muscarinic M4 Receptor As an Approach to Treating Schizophrenia
(12) Patent Application Publication (10) Pub. No.: US 2017/0095465 A1 Elenko Et Al
Practice Parameter: Management of Dementia (An Evidence-Based Review)
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
Molecular Mechanisms of Action and in Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties
Muscarinic Acetylcholine Receptors: Novel Opportunities for Drug Development Andrew C
Karuna Pharmaceuticals and Puretech Health Announce Positive Results
Pharmacological Investigations on Muscarinic and P2 Receptor Subtypes
Curriculum Vitae
Muscarinic Acetylcholine Receptor
Xanomeline (LY246708) Protocol H2Q-MC-LZZT(C)
UNO Template
Wo 2007/044693 A2
Statistical Analysis Plan for Interventional Studies
Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model
Neurogenesis Via Modulation of the Muscarinic Receptors
Effect of the Ligand in the Modeling the 3D Structure of the M3 Muscarinic Receptor
(12) Patent Application Publication (10) Pub. No.: US 2017/0056347 A1 Glick Et Al
Topic 10 Drugs of the Nervous System
Karxt (A New Mechanism Antipsychotic Based on Xanomeline), Is Superior to Placebo in Patients with Schizophrenia: Phase 2 Clinical Trial Results
The M1/M4 Agonist Xanomeline Modulates Functional Connectivity and NMDAR Antagonist‐Induced Changes in the Mouse Brain
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Cholinergic Overstimulation Attenuates Rule Selectivity in Macaque Prefrontal Cortex
2017 Medicines in Development for Mental Illnesses
Harmonized Tariff Schedule of the United States (2006) (Rev
Harmonized Tariff Schedule of the United States (2003) -- Supplement 1 Annotated for Statistical Reporting Purposes
Anticholinergic Medications and Cognition in Older Adults
Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds Piperidinylamino-Thieno[2,3-D]-Pyrimidinverbindungen Composés Pipéridinylamino-Thiéno[2,3-D]Pyrimidines
Designing Hybrids Targeting the Cholinergic System by Modulating the Muscarinic and Nicotinic Receptors: a Concept to Treat Alzheimer’S Disease
The Muscarinic M1/M4 Receptor Agonist Xanomeline Exhibits Antipsychotic-Like Activity in Cebus Apella Monkeys
Le Traitement Pharmacologique Des Déficits Neurocognitifs Associés À La Schizophrénie Et Aux Troubles Psycho,Tiques Apparentés